Moderna's stock has seen a decline following reports of a data leak related to its experimental cancer vaccine, developed in collaboration with Merck. The companies are set to present Phase 3 trial data at an upcoming medical conference this weekend.
The leak has raised concerns among investors about the potential implications for the vaccine's efficacy and market reception. The upcoming presentation is crucial for assessing the future trajectory of this partnership and the vaccine's role in cancer treatment.